Cartalax is a bioregulator peptide targeting cartilage and connective tissue — part of the Khavinson series of tissue-specific short peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. Its precise amino acid sequence activates gene transcription in chondrocytes and connective tissue cells that has been suppressed by aging, mechanical stress, and inflammatory signaling — the epigenetic root of progressive joint degeneration.

Articular cartilage presents one of the most challenging tissue maintenance problems in the body: it is avascular, meaning it receives no direct blood supply and relies on diffusion from synovial fluid for nutrient delivery. This limited nutrition, combined with the compressive loads experienced in daily movement, makes cartilage uniquely susceptible to accumulative damage. Chondrocytes — the sole cell type in cartilage — have limited replicative capacity and declining synthetic activity with age, progressively reducing the rate at which type II collagen and aggrecan (the key extracellular matrix components that give cartilage its load-bearing properties) are replaced.

Cartalax acts by penetrating chondrocyte nuclei and binding to histone-DNA complexes, activating transcription of genes for collagen synthesis, proteoglycan production, and chondrocyte differentiation markers. This epigenetic reactivation restores the cell's ability to produce and maintain the extracellular matrix proteins responsible for cartilage mechanical properties. In animal studies, Cartalax treatment produced measurable increases in cartilage matrix density, improved chondrocyte viability, and reduced markers of cartilaginous degeneration — effects sustained well beyond the treatment period.

Beyond direct cartilage effects, Cartalax influences the broader connective tissue environment. Connective tissue bioregulators like Cartalax also affect fibroblast activity in joint capsule, ligament, and tendon tissue — supporting the entire periarticular connective tissue complex rather than cartilage alone. This comprehensive connective tissue trophic effect makes Cartalax relevant not only for joint degeneration but also for ligament and tendon repair following injury, and for maintaining connective tissue integrity throughout the musculoskeletal system with aging.

The clinical relevance extends to bone-cartilage interface health. Subchondral bone quality is a critical determinant of cartilage health — mechanical signaling from degenerated subchondral bone accelerates cartilage breakdown. Cartalax's connective tissue effects include support for the bone-cartilage interface, addressing the bidirectional relationship between bone quality and cartilage preservation.

Standard protocol involves 2mg/day for 10 consecutive days, administered subcutaneously or intranasally, with cycles repeated 2–4 times per year. For active joint rehabilitation following injury, more frequent initial cycling (every 3 months in the first year) is typically employed. Cartalax combines synergistically with BPC-157 (which promotes connective tissue healing through growth factor upregulation) and TB-500 (actin-mediated tissue repair) — the epigenetic restoration of chondrocyte synthetic capacity provided by Cartalax complements the growth factor and actin-mediated repair mechanisms of these healing peptides.